Benzinga | Feb 11, 2021 04:02PM EST

Avita Therapeutics Q2 EPS $(0.26) Beats $(0.43) Estimate, Sales $5.10M Miss $5.60M Estimate

Avita Therapeutics (NASDAQ:RCEL) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.43) by 39.53 percent. The company reported quarterly sales of $5.10 million which missed the analyst consensus estimate of $5.60 million by 8.93 percent.